Correspondence 0001193125-25-014242 from Maze Therapeutics, Inc. (MAZE) (CIK 0001842295) (MAZE)
Maze Therapeutics, Inc. (MAZE) (CIK 0001842295)
Date: Jan. 28, 2025 · CIK: 0001842295 · Accession: 0001193125-25-014242
AI Filing Summary & Sentiment
File numbers found in text: 333-284164
Letter
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
TD Securities (USA) LLC
1 Vanderbilt Avenue, 11th Floor
New York, New York 10017
Leerink Partners LLC
255 California Street, 12th Floor
San Francisco, California 94111
Guggenheim Securities, LLC
330 Madison Avenue
New York, New York 10017
January 28, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention:
Jimmy McNamara
Suzanne Hayes
Sasha Parikh
Kevin Vaughn
Re: Maze Therapeutics, Inc. (the “Registrant”)
Registration Statement on Form S-1, as amended (File No. 333-284164)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of the Registrant for acceleration of the effective date of the above-referenced Registration Statement on Form S-1, as amended, so that it becomes effective as of 4:00 p.m. Eastern time on January 30, 2025, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Fenwick & West LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature page follows]
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 TD Securities (USA) LLC 1 Vanderbilt Avenue, 11th Floor New York, New York 10017 Leerink Partners LLC 255 California Street, 12th Floor San Francisco, California 94111 Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 January 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jimmy McNamara Suzanne Hayes Sasha Parikh Kevin Vaughn Re: Maze Therapeutics, Inc. (the “Registrant”) Registration Statement on Form S-1, as amended (File No. 333-284164) Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of the Registrant for acceleration of the effective date of the above-referenced Registration Statement on Form S-1, as amended, so that it becomes effective as of 4:00 p.m. Eastern time on January 30, 2025, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Fenwick & West LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Signature page follows] Very truly yours, J.P. MORGAN SECURITIES LLC TD SECURITIES (USA) LLC LEERINK PARTNERS LLC GUGGENHEIM SECURITIES, LLC As representatives of the several underwriters listed in Schedule 1 of the Underwriting Agreement J.P. MORGAN SECURITIES LLC By: /s/ Benjamin Burdett Authorized Signatory Name: Benjamin Burdett Title: Managing Director, Head of Healthcare ECM TD SECURITIES (USA) LLC By: /s/ Bill Follis Authorized Signatory Name: Bill Follis Title: Managing Director LEERINK PARTNERS LLC By: /s/ Dan Dubin Authorized Signatory Name: Dan Dubin Title: Vice Chairman GUGGENHEIM SECURITIES, LLC By: /s/ Shiv Taylor, M.D. Authorized Signatory Name: Shiv Taylor, M.D. Title: Senior Managing Director [Signature Page to Underwriters’ Acceleration Request Letter]